Navigation Links
PhRMA Launches Campaign to Raise Awareness of Success of Medicare Prescription Drug Benefit
Date:6/10/2009

WASHINGTON, June 10 /PRNewswire-USNewswire/ -- With the debate over comprehensive healthcare reform now in full swing, the Pharmaceutical Research and Manufacturers of America is launching a new national broadcast advertising campaign touting the importance and success of free-market initiatives such as the Medicare prescription drug benefit (Part D).

Medicare Part D continues to provide unprecedented coverage and choice for seniors and disabled Americans, according to national surveys. And most importantly, seniors are saving money on their medicines through the program, particularly those who need it the most. According to the Centers for Medicare and Medicaid Services (CMS), the average value of the Part D benefit, premium subsidy, and cost-sharing subsidy in 2009 will be $1,200 for the average beneficiary, and about $3,900 for low-income.

In fact, in 2009, approximately 97 percent of beneficiaries in a stand-alone plan have access to a monthly premium less or equal to the premium they paid in 2008, according to CMS. And every state offers a Medicare prescription drug plan with a premium of $23 or less.

A recent Medicare Today survey, cited in the commercial, shows overall satisfaction has grown from 78 percent at the start of the program in 2006, to 84 percent in 2009. In addition, the new commercial also pushes for comprehensive healthcare reform.

"There is a success story out there in healthcare, and we want people to know about it. Since its inception, the Medicare drug benefit has given beneficiaries unprecedented access to needed medications, at an affordable cost," said PhRMA Senior Vice President Ken Johnson.

Not only are Medicare beneficiaries saving significant money, so too are American taxpayers. In March 2009, the non-partisan Congressional Budget Office (CBO) released new baseline spending projections that reduced its 10-year forecast for the total cost of the Medicare drug program by $520 billion, or 43 percent, compared with its 2006 estimate for the same 10-year period (FY 2007-2016).

"PhRMA echoes the sentiment shared by President Obama and members of Congress that it is critical that all Americans have access to high-quality and affordable healthcare coverage and will do everything we can to help ensure that a comprehensive healthcare reform bill gets to the White House this year," said PhRMA President and CEO Billy Tauzin.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $50.3 billion in 2008 in discovering and developing new medicines. Industry-wide research and investment reached a record $65.2 billion in 2008.

PhRMA Internet Address: http://www.phrma.org

For information on stories of hope and survival, visit: http://sharingmiracles.com/

For information on how innovative medicines save lives, visit: http://www.innovation.org

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org

For more information on public health emergencies, visit http://www.rxresponse.org

For information on the danger of imported drugs, visit:http://www.buysafedrugs.info


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PhRMA Statement on Healthcare Reform Coalition
2. American Slide Chart/Perrygraf "SlideGuides" and "SpinGuides" Help Drug Companies Satisfy New PhRMA Guidelines
3. PhRMA Honors Gardasil(r) Researchers With Discoverers Award
4. AstraZenecas David Brennan Elected PhRMA Board Chairman
5. PhRMA Statement on Expansion of SCHIP
6. DIA/FDA/PhRMA Drug Safety Conference: Planning the Lifecycle of Safety Evaluation
7. Revised PhRMA Marketing Code Calls for More Educational Materials for Health Care Providers and Staff - Anatstat Health Education Can Help
8. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
9. Johnson & Johnson Announces Commitment To Adopt Revised PhRMA Marketing Code for Responsible Interactions With Healthcare Professionals
10. PhRMA Revised Marketing Code Reinforces Commitment to Responsible Interactions With Healthcare Professionals
11. Richard T. Clark Elected PhRMA Board Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... 2017 , ... Guide to FDA and EU Medical Device Regulations: 2017 Edition, ... of the Atlantic devicemakers do business, this fully updated and expanded guide keeps them ... to the full text of the FDA’s regulations in 21 CFR Parts 800 to ...
(Date:6/28/2017)... ... ... David B. Sosin, a founding partner at the law firm Sosin, Arnold ... President for the Illinois State Bar Association , in accordance with the organization’s rules ... 2016 following a state-wide election and served in that capacity for the past year prior ...
(Date:6/28/2017)... Columbia (PRWEB) , ... June 28, 2017 , ... ... (FSE: ZEON) is pleased to announce that a two year study conducted by ... Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a ...
(Date:6/28/2017)... ... June 28, 2017 , ... The Dianne ... the greater Cincinnati metropolitan area, is teaming up with the local chapter of ... children receiving treatment in nearby hospitals. , Ronald McDonald House of Greater Cincinnati, ...
(Date:6/27/2017)... ... 27, 2017 , ... Harbour , a DAO (decentralized autonomous organization) that ... has released their technical specifications . , 2017 has seen an explosion of ... for determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ) today ... R. Goodwin , U.S. District Court Judge for the ... entered a case management order in MDL 2325, American ... (the "MDL") that includes a provision requiring plaintiffs in ... specific causation within one hundred twenty (120) days of ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences ... Company specializing in the development of cannabinoid-based drugs, ... a company overview at three upcoming scientific and ... Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: